- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04802785
The Impact of Air Travel on Passenger Cognitive Functions
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: Citicoline
- Médicament: Cytochrome C6
- Médicament: Sodium Chloride Oral Product
- Médicament: Potassium Chloride Oral Product
- Médicament: Sodium Citrate Oral Product
- Médicament: Dextrose Oral Tablet, Chewable
- Médicament: Domperidone Oral Product
- Médicament: Simethicone
- Médicament: Acetylsalicylic acid
- Médicament: Magnesium hydroxide
- Médicament: Probiotic Formula
- Médicament: Melatonin 5 mg
Type d'étude
Inscription (Anticipé)
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Study participants (Volunteers) will be recruited through media, advertisements and announcements. Prior to the study, study participants will receive written and oral explanations of the study protocols, and written informed consent will be obtained from each study participant. All potential research participants will undergo medical and psychological selection. The components, stages of selection are almost the same as those of general professional selection: the first stage is professiography / psychogram, the second stage is psychodiagnostics, the third stage is assessment and forecasting, and the fourth stage is decision making. Selection will assess the ability of participants to perform complex sequential actions.
Inclusion criterion:
- Age from 22 to 30 years old;
- at least 15 years of education, including secondary education;
- understand and speak Russian (Due to the valid Russian-language questionnaire and methodology).
In addition, study participants will be asked not to limit their caffeine intake from their daily intake, but only water is allowed 4 hours before the neuropsychological testing. Participants in the study should not hmedical/medicallane in the last two weeks prior to the start of the study, nor should they consume alcohol during the study.
Exclusion criterion:
- A member taking melatonin (affects circadian rhythm);
- Participant with comorbidities that affect cognitive function and sleep (eg, stroke, TIA, concussion with loss of consciousness, hearing problems, chronic fatigue syndrome, depression, seasonal affective disorder, anorexia);
- A participant with another ongoing sleep disorder.
All participants must be free of a history of venous thrombosis, antithrombotic or anticoagulant medications and oral contraceptives and / or any other drugs that interfere with blood coagulation (i.e. warfarin, coumadin) for at least 2 months prior to study initiation, and sign a consent to refrain from taking medications that may affect coagulation, such as aspirin or non-steroidal anti-inflammatory drugs, within 3 days after the flight, unless there is a medical / medical need.
-
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: The study Group
|
Citicoline 500 mg (Vitaae®) per os
Autres noms:
Cytochrome10 mg per os
Autres noms:
Sodium Chloride (NaCl) 2.6 g. per os
Potassium Chloride 1.5 g per os
Autres noms:
Sodium Citrate 2.90 g per os
Autres noms:
Dextrose 13.5 g per os
Autres noms:
Domperidone 1 tablet per os
Autres noms:
3-4 capsules per os
Autres noms:
Acetylsalicylic acid 150 mg per os
magnesium hydroxide 30 mg per os
1 capsule per os.
Autres noms:
|
|
Comparateur actif: Control group
Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.
|
Melatonin 5 mg per os.
Autres noms:
|
|
Aucune intervention: Explanatory group:
12 participants without any intervention.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Urine Specific Gravity
Délai: 24 hours before the flight
|
Urine Specific Gravity test
|
24 hours before the flight
|
|
SpO2 level
Délai: 24 hours before the flight
|
Pulse oximetry
|
24 hours before the flight
|
|
Ultrasound examination
Délai: 24 hours before the flight
|
Ultrasound examination of the veins of the lower limbs
|
24 hours before the flight
|
|
The Liverpool Jet Lag questionnaire
Délai: 24 hours before the flight
|
Changes from normal (0 to 5) while jetlag rating was recorded on a scale from 0 = insignificant jetlag to 10 = severe jetlag
|
24 hours before the flight
|
|
Lake Louise Acute Mountain Sickness Assessment System
Délai: 24 hours before the flight
|
Mild acute mountain sicknessas 3-5 points, moderate acute mountain sickness as 6-9 points, and severe acute mountain sickness as 10-12 points
|
24 hours before the flight
|
|
Neuropsychological tests (Trail Making Test, Wechsler Memory Scale - IV, Free recall
Délai: 24 hours after the flight
|
Word, color, and color-word T-Scores of 40 or less are considered "low."
Word, color, and color-word T-Scores above 40 or are considered "normal."
In order for one score to be considered "higher" or "lower" than another, a 10 point or greater T score difference is required.
|
24 hours after the flight
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
SpO2 level
Délai: 24 hours before the flight
|
Pulse oximetry
|
24 hours before the flight
|
|
The Liverpool Jet Lag questionnaire (LJLQ)
Délai: 24 hours after the flight
|
Changes from normal (0 to 5) while jetlag rating was recorded on a scale from 0 = insignificant jetlag to 10 = severe jetlag
|
24 hours after the flight
|
|
Lake Louise Acute Mountain Sickness Assessment System
Délai: 24 hours after the flight
|
Mild acute mountain sicknessas 3-5 points, moderate acute mountain sickness as 6-9 points, and severe acute mountain sickness as 10-12 points
|
24 hours after the flight
|
|
The Stroop Test
Délai: 24 hours after the flight
|
Word, color, and color-word T-Scores of 40 or less are considered "low."
Word, color, and color-word T-Scores above 40 or are considered "normal."
In order for one score to be considered "higher" or "lower" than another, a 10 point or greater T score difference is required.
|
24 hours after the flight
|
|
Urine Specific Gravity
Délai: 24 hours after the flight
|
Urine Specific Gravity test
|
24 hours after the flight
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Effets physiologiques des médicaments
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Dépresseurs du système nerveux central
- Agents autonomes
- Agents du système nerveux périphérique
- Inhibiteurs d'enzymes
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires non stéroïdiens
- Analgésiques, non narcotiques
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Agents fibrinolytiques
- Agents modulateurs de fibrine
- Inhibiteurs de l'agrégation plaquettaire
- Inhibiteurs de la cyclooxygénase
- Antipyrétiques
- Antiémétiques
- Agents gastro-intestinaux
- Agents protecteurs
- Agents dermatologiques
- Agents dopaminergiques
- Antagonistes de la dopamine
- Anticoagulants
- Antioxydants
- Agents antimoussants
- Émollients
- Agents chélatants
- Agents séquestrants
- Agents nootropes
- Agents chélateurs de calcium
- Antiacides
- Aspirine
- Mélatonine
- Siméthicone
- L'hydroxyde de magnésium
- Dompéridone
- Acide citrique
- Citrate de sodium
- Cytidine Diphosphate Choline
Autres numéros d'identification d'étude
- 1 (Mobile Health and Wellness Program)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .